300122 智飞生物
已收盘 07-24 15:00:00
资讯
新帖
简况
智飞生物：截至2026年7月20日，公司普通股股东人数为114,348
证券之星 · 07-24 16:51
智飞生物：截至2026年7月20日，公司普通股股东人数为114,348
智飞生物最新公告：拟以1.5亿元至3亿元回购公司股份
证券之星 · 07-20
智飞生物最新公告：拟以1.5亿元至3亿元回购公司股份
智飞生物：公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局
证券之星 · 07-17
智飞生物：公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局
智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发
证券之星 · 07-17
智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发
智飞生物：聚焦生产经营稳健发展
证券之星 · 07-17
智飞生物：聚焦生产经营稳健发展
智飞生物：自主产品涵盖预防流脑、流感等传染病的疫苗
证券之星 · 07-17
智飞生物：自主产品涵盖预防流脑、流感等传染病的疫苗
智飞生物最新公告：控股子公司利拉鲁肽注射液获药品注册证书
证券之星 · 07-10
智飞生物最新公告：控股子公司利拉鲁肽注射液获药品注册证书
智飞生物：始终坚持自主研发为主、合作研发为辅、投资孵化为补
证券之星 · 07-10
智飞生物：始终坚持自主研发为主、合作研发为辅、投资孵化为补
智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发
证券之星 · 07-10
智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发
智飞生物：聚焦生产经营稳健发展
证券之星 · 07-10
智飞生物：聚焦生产经营稳健发展
智飞生物：公司搭建了“七+N”技术平台
证券之星 · 07-10
智飞生物：公司搭建了“七+N”技术平台
智飞生物：公司的控股子公司宸安生物聚焦糖尿病、肥胖等代谢类疾病领域
证券之星 · 07-10
智飞生物：公司的控股子公司宸安生物聚焦糖尿病、肥胖等代谢类疾病领域
7月10日智飞生物涨7.04%，疫苗ETF嘉实基金重仓该股
证券之星 · 07-10
7月10日智飞生物涨7.04%，疫苗ETF嘉实基金重仓该股
智飞生物：公司持续加快产品创新，强化核心竞争力
证券之星 · 07-03
智飞生物：公司持续加快产品创新，强化核心竞争力
智飞生物：公司2026年半年度报告预约于2026年8月18日披露
证券之星 · 07-03
智飞生物：公司2026年半年度报告预约于2026年8月18日披露
智飞生物：公司已经根据法规要求制定了《市值管理制度》
证券之星 · 07-03
智飞生物：公司已经根据法规要求制定了《市值管理制度》
智飞生物：自去年以来，公司采取一系列措施促进公司生产经营稳健发展
证券之星 · 07-03
智飞生物：自去年以来，公司采取一系列措施促进公司生产经营稳健发展
智飞生物（300122）披露控股股东部分股份补充质押公告，6月26日股价下跌5.17%
证券之星 · 06-26
智飞生物（300122）披露控股股东部分股份补充质押公告，6月26日股价下跌5.17%
6月26日智飞生物跌5.17%，疫苗ETF嘉实基金重仓该股
证券之星 · 06-26
6月26日智飞生物跌5.17%，疫苗ETF嘉实基金重仓该股
股市必读：智飞生物（300122）6月18日董秘有最新回复
证券之星 · 06-22
股市必读：智飞生物（300122）6月18日董秘有最新回复
加载更多
公司概况
公司名称：
重庆智飞生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2010-09-28
主营业务：
重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。
发行价格：
37.98
{"stockData":{"symbol":"300122","market":"SZ","secType":"STK","nameCN":"智飞生物","latestPrice":12.13,"timestamp":1784876592000,"preClose":12.68,"halted":0,"volume":21158998,"delay":0,"changeRate":-0.0434,"floatShares":1414000000,"shares":2394000000,"eps":-6.1778,"marketStatus":"已收盘","change":-0.55,"latestTime":"07-24 15:00:00","open":12.6,"high":12.7,"low":12.13,"amount":262000000,"amplitude":0.045,"askPrice":12.14,"askSize":84,"bidPrice":12.13,"bidSize":561,"shortable":0,"etf":0,"ttmEps":-6.1778,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":5,"adr":0,"adjPreClose":12.68,"symbolType":"stock","openAndCloseTimeList":[[1784856600000,1784863800000],[1784869200000,1784876400000]],"highLimit":13.95,"lowLimit":11.41,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":2393789747,"isCdr":false,"pbRate":1.96,"roa":"--","roe":"--","epsLYR":-6.1506,"committee":0.150705,"marketValue":29037000000,"turnoverRate":0.015,"status":1,"floatMarketCap":17156000000},"requestUrl":"/m/hq/s/300122","defaultTab":"news","newsList":[{"id":"2653700979","title":"智飞生物：截至2026年7月20日，公司普通股股东人数为114,348","url":"https://stock-news.laohu8.com/highlight/detail?id=2653700979","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653700979?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:51","pubTimestamp":1784883078,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月24日在投资者关系平台上答复投资者关心的问题。投资者提问：您好！请问截至7月10日和7月20日收盘公司股东人数分别是多少，谢谢！智飞生物回复：您好，截至2026年7月20日，公司普通股股东人数为114,348，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400028937.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2148510915.USD","300122","LU2580892789.USD","LU1328615791.USD","LU1064131003.USD","LU1064130708.USD","BK0046","LU2580892862.HKD","BK0239","BK0188","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652916297","title":"智飞生物最新公告：拟以1.5亿元至3亿元回购公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2652916297","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652916297?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:50","pubTimestamp":1784544608,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司董事会审议通过回购股份方案，拟以自有或自筹资金不低于1.5亿元且不超过3亿元，通过集中竞价方式回购A股股份，用于股权激励或员工持股计划。回购价格不超过18.22元/股，实施期限为12个月。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000031727.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0188","BK0077","LU2580892789.USD","300122","LU2148510915.USD","LU1064130708.USD","BK0046","LU1064131003.USD","BK0239","LU2580892862.HKD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652740939","title":"智飞生物：公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2652740939","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652740939?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:03","pubTimestamp":1784279036,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，近期XG感染人数不断攀升，专家称病毒在不断进化逃避人体免疫系统屏障，而且在几年前接种XG疫苗人群的药效也在逐步归零，或需重新接种，请问公司目前最新相关疫苗产品都有哪些？智飞生物回复：您好，公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发。公司的研发管线详情请您查阅公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030942.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0077","BK0196","LU2580892789.USD","LU1064130708.USD","LU1064131003.USD","BK0239","300122","LU2580892862.HKD","BK0046","BK0188","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652409515","title":"智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409515","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652409515?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278842,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月17日在投资者关系平台上答复投资者关心的问题。请介绍一下智飞生物回复：您好，公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发。同时，公司参股重庆智睿投资有限公司，积极布局大健康领域，促进前沿生物医药、先进生物技术的研发和产业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","BK0196","BK0188","BK0077","LU2580892862.HKD","159646","LU1064130708.USD","BK0239","LU1328615791.USD","300122","LU2580892789.USD","BK0046","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652095584","title":"智飞生物：聚焦生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2652095584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652095584?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278834,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月17日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，作为行业龙头为什么贵司股价始终涨不过那些小公司？公司市值管理的相关措施有哪些？智飞生物回复：您好，自去年以来，公司聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；同时完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030834.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0077","LU1328615791.USD","300122","LU2580892789.USD","LU2580892862.HKD","BK0046","BK0188","BK0196","LU2148510915.USD","LU1064131003.USD","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652240959","title":"智飞生物：自主产品涵盖预防流脑、流感等传染病的疫苗","url":"https://stock-news.laohu8.com/highlight/detail?id=2652240959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652240959?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278833,"startTime":"0","endTime":"0","summary":"投资者提问：根据公开资料，公司6年前的股价曾到过231元，高股价是因为公司代理的默沙东疫苗当时在国内市场占有率高。如今，公司代理的默沙东疫苗市场逐步被国内的疫苗代替，公司股价6年间跌幅近97%。公司自主产品涵盖预防流脑、流感等传染病的疫苗和提供结核感染诊断、预防、治疗的生物制品，还涵盖用于成人2型糖尿病患者控制血糖等适应症的利拉鲁肽注射液。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030832.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","BK0046","LU1064130708.USD","BK0239","LU2148510915.USD","LU1064131003.USD","BK0196","LU1328615791.USD","BK0188","159646","LU2580892862.HKD","BK0077","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650184112","title":"智飞生物最新公告：控股子公司利拉鲁肽注射液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2650184112","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650184112?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:40","pubTimestamp":1783680014,"startTime":"0","endTime":"0","summary":"智飞生物(300122.SZ)公告称，公司控股子公司宸安生物的利拉鲁肽注射液(商品名：达舒宸)获得国家药监局颁发的药品注册证书，适用于成人2型糖尿病患者控制血糖，适用于降低伴有心血管疾病的2型糖尿病成人患者的主要心血管不良事件（心血管死亡、非致死性心肌梗死或非致死性卒中）风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000036393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","BK0188","LU2580892789.USD","LU1064131003.USD","BK0196","LU1328615791.USD","LU2148510915.USD","LU2580892862.HKD","LU1064130708.USD","300122","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650618598","title":"智飞生物：始终坚持自主研发为主、合作研发为辅、投资孵化为补","url":"https://stock-news.laohu8.com/highlight/detail?id=2650618598","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650618598?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:51","pubTimestamp":1783673484,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月10日在投资者关系平台上答复投资者关心的问题。在自主研发方面，公司已搭建\"七+N\"技术平台，并形成了呼吸道传播疫苗、消化道传播疫苗、结核产品、肿瘤相关性疫苗、多联多价疫苗、成人疫苗、代谢相关性药物等七大产品矩阵。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0196","LU1064131003.USD","LU2148510915.USD","BK0188","LU2580892789.USD","BK0239","LU1064130708.USD","BK0046","300122","BK0077","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650856091","title":"智飞生物：开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2650856091","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650856091?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:51","pubTimestamp":1783673481,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月10日在投资者关系平台上答复投资者关心的问题。智飞生物回复：您好，公司现已形成北京智飞绿竹、安徽智飞龙科马、重庆宸安三大研产基地和北京创新孵化中心的战略布局，开展疫苗、结核类生物制品、GLP-1类似物及胰岛素类似物的创新研发。同时，公司参股重庆智睿投资有限公司，积极布局大健康领域，促进前沿生物医药、先进生物技术的研发和产业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029757.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159646","BK0188","LU2580892862.HKD","BK0077","LU1064130708.USD","LU1328615791.USD","LU1064131003.USD","LU2580892789.USD","300122","BK0239","LU2148510915.USD","BK0046","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650185614","title":"智飞生物：聚焦生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2650185614","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650185614?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:51","pubTimestamp":1783673478,"startTime":"0","endTime":"0","summary":"贵公司的市值管理制度难道是没有任何作用的制度吗？自去年以来，公司聚焦生产经营稳健发展，持续开展产品创新，巩固核心竞争力；优化市场营销策略，提升商业推广效能；完善治理体系，强化全过程质量管理，为企业长远发展奠定坚实基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029754.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300122","BK0046","LU1328615791.USD","BK0077","LU2580892789.USD","LU1064131003.USD","LU2148510915.USD","BK0196","BK0188","LU1064130708.USD","LU2580892862.HKD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650185543","title":"智飞生物：公司搭建了“七+N”技术平台","url":"https://stock-news.laohu8.com/highlight/detail?id=2650185543","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650185543?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:48","pubTimestamp":1783673305,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司mRNA技术平台和重组蛋白等前沿技术储备，是否具备更高的商业价值？智飞生物回复：您好，公司搭建了“七+N”技术平台，囊括多糖蛋白结合技术平台、mRNA技术平台、多联多价技术平台等，广泛覆盖多元研发路径，优化资源配置，为各项目高效推进筑牢技术基础。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029661.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0239","LU1328615791.USD","BK0188","LU2580892789.USD","BK0196","LU1064130708.USD","LU1064131003.USD","LU2580892862.HKD","LU2148510915.USD","BK0046","300122"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650185521","title":"智飞生物：公司的控股子公司宸安生物聚焦糖尿病、肥胖等代谢类疾病领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2650185521","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650185521?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:48","pubTimestamp":1783673300,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物(300122)07月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，贵公司GLP-1类产品，还要多久能上市销售！智飞生物回复：您好，公司的控股子公司宸安生物聚焦糖尿病、肥胖等代谢类疾病领域，围绕GLP-1类似物、胰岛素类似物等领域布局。在研产品进展请持续关注公司的信息披露，谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029658.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","BK0046","BK0188","BK0239","LU1328615791.USD","LU1064130708.USD","LU2580892862.HKD","300122","LU2148510915.USD","BK0196","BK0077","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650183427","title":"7月10日智飞生物涨7.04%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650183427","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650183427?lang=zh_cn&edition=full","pubTime":"2026-07-10 16:32","pubTimestamp":1783672379,"startTime":"0","endTime":"0","summary":"证券之星消息，7月10日智飞生物涨7.04%，收盘报12.17元，换手率3.12%，成交量44.09万手，成交额5.28亿元。重仓智飞生物的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为嘉实基金的疫苗ETF嘉实。疫苗ETF嘉实目前规模为2.25亿元，最新净值0.6234，较上一交易日上涨0.53%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000029168.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","562860","LU2148510915.USD","LU1328615791.USD","300122","BK0046","LU2580892862.HKD","BK0077","LU1064131003.USD","LU2580892789.USD","BK0196","BK0239","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648578776","title":"智飞生物：公司持续加快产品创新，强化核心竞争力","url":"https://stock-news.laohu8.com/highlight/detail?id=2648578776","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648578776?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:06","pubTimestamp":1783069568,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月03日在投资者关系平台上答复投资者关心的问题。自去年以来，公司采取一系列措施促进公司生产经营稳健发展。公司持续加快产品创新，强化核心竞争力；优化市场策略，强化商业推广；提升治理水平，扎实做好质量管理，夯实企业发展根基。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030926.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","LU2580892789.USD","LU1064131003.USD","LU2580892862.HKD","BK0196","BK0239","300122","LU1328615791.USD","BK0077","BK0188","BK0046"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648965735","title":"智飞生物：公司2026年半年度报告预约于2026年8月18日披露","url":"https://stock-news.laohu8.com/highlight/detail?id=2648965735","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648965735?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:01","pubTimestamp":1783069286,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月03日在投资者关系平台上答复投资者关心的问题。与此同时，公司股票从最高点231元算起，6年跌幅近97%在5000多只股票里面跌幅第一，且股价一直破位下跌创新低。请问：公司今年8月份是否能正常出半年报，是否半年报后面临摘牌风险？！智飞生物回复：你好，公司2026年半年度报告预约于2026年8月18日披露，公司经营业绩请持续关注公司的定期报告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030797.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","BK0239","300122","BK0046","BK0188","BK0077","LU2148510915.USD","LU1328615791.USD","LU1064131003.USD","LU2580892789.USD","LU1064130708.USD","LU2580892862.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648652079","title":"智飞生物：公司已经根据法规要求制定了《市值管理制度》","url":"https://stock-news.laohu8.com/highlight/detail?id=2648652079","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648652079?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:57","pubTimestamp":1783069061,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月03日在投资者关系平台上答复投资者关心的问题。投资者提问：根据《上市公司监管指引第10号》第十四条：主要指数成份股公司——必须制定市值管理制度；长期破净公司——必须披露估值提升计划。公司市值屡创新低，管理层却借口二级市场的波动，这明显是经营不善造成。公司通过完善公司治理、改善经营管理，实现公司稳健可持续发展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU1064130708.USD","BK0046","LU2148510915.USD","300122","LU1328615791.USD","BK0077","BK0239","LU2580892862.HKD","LU1064131003.USD","BK0188","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648434652","title":"智飞生物：自去年以来，公司采取一系列措施促进公司生产经营稳健发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2648434652","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648434652?lang=zh_cn&edition=full","pubTime":"2026-07-03 16:48","pubTimestamp":1783068529,"startTime":"0","endTime":"0","summary":"证券之星消息，智飞生物07月03日在投资者关系平台上答复投资者关心的问题。而公司最近2年通过互动易回答投资者的提问时，总是说公司生产经营一切正常。公司生产经营正常，为啥公司股票6年跌幅近97%？自去年以来，公司采取一系列措施促进公司生产经营稳健发展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2580892789.USD","LU1064131003.USD","LU2148510915.USD","LU2580892862.HKD","BK0239","BK0188","300122","BK0077","LU1328615791.USD","BK0196","BK0046","LU1064130708.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646035548","title":"智飞生物（300122）披露控股股东部分股份补充质押公告，6月26日股价下跌5.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2646035548","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646035548?lang=zh_cn&edition=full","pubTime":"2026-06-26 17:50","pubTimestamp":1782467459,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，智飞生物报收于11.38元，较前一交易日下跌5.17%，最新总市值为272.41亿元。公告显示，公司控股股东蒋仁生将其持有的公司45,000,000股股份进行补充质押，占其所持股份比例3.88%，占公司总股本比例1.88%。质押股份性质为董事锁定股，质权人为重庆农村商业银行股份有限公司，质押起始日为2026年6月24日，到期日为2030年11月7日。本次质押后，蒋仁生累计质押股份184,350,000股，占其所持股份比例15.90%，占公司总股本比例7.70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600033094.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","300122","LU1064131003.USD","LU2580892789.USD","BK0046","LU1328615791.USD","LU2148510915.USD","LU2580892862.HKD","BK0239","BK0077","BK0196","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646586703","title":"6月26日智飞生物跌5.17%，疫苗ETF嘉实基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2646586703","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646586703?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:55","pubTimestamp":1782464129,"startTime":"0","endTime":"0","summary":"证券之星消息，6月26日智飞生物跌5.17%创60日新低，收盘报11.38元，换手率1.76%，成交量24.87万手，成交额2.9亿元。疫苗ETF嘉实目前规模为2.25亿元，最新净值0.6065，较上一交易日下跌0.21%，近一年上涨13.79%。疫苗ETF嘉实的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","300122","LU1064131003.USD","LU2580892862.HKD","562860","BK0077","LU2148510915.USD","BK0239","BK0046","LU1064130708.USD","BK0196","LU1328615791.USD","LU2580892789.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645155050","title":"股市必读：智飞生物（300122）6月18日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2645155050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645155050?lang=zh_cn&edition=full","pubTime":"2026-06-22 02:55","pubTimestamp":1782068110,"startTime":"0","endTime":"0","summary":"截至2026年6月18日收盘，智飞生物报收于12.21元，下跌3.17%，换手率1.8%，成交量25.43万手，成交额3.15亿元。董秘最新回复投资者： 请问董秘，公司是否涉及销售医疗器械相关产品？董秘： 您好，截至2026年6月10日，公司普通股股东人数为114,160，谢谢！该疫苗用于预防婴幼儿及儿童轮状病毒感染引起的急性胃肠炎，采用注射途径免疫，具有免疫原性稳定、持久等特点。目前该事项对公司近期业绩无重大影响，后续进展存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062200001026.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1328615791.USD","BK0077","BK0196","LU2580892789.USD","LU1064130708.USD","LU1064131003.USD","BK0239","300122","LU2580892862.HKD","BK0046","BK0188","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1784931630850,"stockEarnings":[{"period":"1week","weight":-0.0114},{"period":"1month","weight":0.0151},{"period":"3month","weight":-0.1804},{"period":"6month","weight":-0.298},{"period":"1year","weight":-0.5103},{"period":"ytd","weight":-0.3572}],"compareEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":-0.0722},{"period":"3month","weight":-0.0651},{"period":"6month","weight":-0.0778},{"period":"1year","weight":0.0578},{"period":"ytd","weight":-0.039}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智飞生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"114348人(较上一季度增加0.26%)","perCapita":"12368股","listingDate":"2010-09-28","address":"重庆市两江新区庆云路1号50层","registeredCapital":"239378万元","survey":" 重庆智飞生物制品股份有限公司的主营业务是疫苗、生物制品研发、生产、销售、推广、配送及进出口。公司的主要产品是盟威克、盟纳康、喜菲贝、盟纳克、智克威得、宜卡、微卡、优威克、四价流感病毒裂解疫苗、佳达修、佳达修9、乐儿德、纽莫法、维康特、欣安立适。","listedPrice":37.98},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智飞生物,300122,智飞生物股票,智飞生物股票老虎,智飞生物股票老虎国际,智飞生物行情,智飞生物股票行情,智飞生物股价,智飞生物股市,智飞生物股票价格,智飞生物股票交易,智飞生物股票购买,智飞生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智飞生物(300122)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智飞生物(300122)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}